BIO-TECHNE Corp, commonly known by its ticker symbol TECH, is a global life sciences company dedicated to empowering researchers in the pursuit of scientific advances with its high-quality reagent tools, instruments, and services. The Minneapolis-based company, established in 1976, has positioned itself as a leading player in the modern biotechnology landscape.
TECH's product portfolio offers an end-to-end solution, spanning the entire scope of the biology-based research landscape, from initial investigations to translational research and clinical diagnostic applications. It focuses on the development, manufacture, and sale of biotechnology products and diagnostic instruments, geared towards both basic research and commercial applications. The company’s product range primarily includes proteins, such as cytokines and growth factors, antibodies, commercial kits, and other reagent solutions.
The company operates globally across a multitude of scientific sectors, providing crucial tools for scientists to make impactful discoveries in critical areas of biology, including stem cell science, cancer, and cell and gene therapies. Moreover, it also supports researchers with protein analysis, gene expression, and other cellular research applications.
What essentially distinguishes BIO-TECHNE Corp is its unwavering commitment to quality, reflected in the company's careful selection of raw materials and rigorous quality control procedures, which ensures the efficacy and consistency of their products.
The company has a well-established presence in the international market and has expanded its footprint through strategic acquisitions and partnerships, which have allowed it to broaden its product portfolio and reach. The acquisitions of renowned brands like R&D Systems, Novus Biologicals, ProteinSimple, and Advanced Cell Diagnostics over the years have significantly propelled BIO-TECHNE Corp's growth trajectory and consolidated its position in the biotechnology sector.
Even in the challenging environment of the COVID-19 pandemic, BIO-TECHNE Corp managed to sustain its operations and continue its growth, mainly driven by strong demand for its COVID-19 antibodies and reagents.
As a progressive R&D driven company, it consistently invests in technological advancements and inventive solutions designed to push the boundaries of biomedical research and enable the acceleration of discovery. In terms of governance, the company operates under the leadership of a team of seasoned executives with vast industry experience, guiding TECH towards its purpose of putting engineering and precision manufacturing to work to create a healthier, better world.
In conclusion, BIO-TECHNE Corp, with its comprehensive portfolio of quality products and its dedication to fueling scientific discovery, is making a profound contribution to the biotechnology field and beyond. It is a go-to partner for researchers and a formidable contender in the life sciences industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Bio-Techne (TECH) shareholders have approved the acquisition of the company by Merck KGaA for $73 a share, valuing the business at approximately $11.3 billion. Simultaneously, shareholders rejected the executive compensation proposal tied to the deal, signaling their disapproval of the pay arrangements. The deal is expected to close in late 2026 or early 2027, pending remaining regulatory approvals outside the U.S., with the focus now shifting from price to timing for investors.
Robert V Baumgartner, a Board Member at Bio-Techne (NASDAQ: TECH), exercised stock options for 15,940 shares, valued at $754,759. The transaction was disclosed in an SEC filing on September 24. Bio-Techne specializes in life sciences manufacturing, serving pharmaceutical, biotech, academic, and diagnostic markets, with its protein sciences segment being the largest revenue contributor.
Shareholders of Bio-Techne Corporation have approved the definitive merger agreement for Merck KGaA to acquire the company for approximately USD 11.3 billion. This all-cash deal, valued at USD 73.00 per share, represents Merck KGaA's largest acquisition since 2015 and an important strategic move under its new CEO. While the US antitrust waiting period has expired, regulatory reviews in other jurisdictions are ongoing, with closing expected in late 2026 or early 2027.
Bio-Techne Corporation shareholders have approved the definitive agreement for Merck KGaA, Darmstadt, Germany to acquire the company. This marks a significant step towards completing the transaction, which is expected to close by late 2026 or early 2027, pending regulatory approvals. The acquisition aims to combine complementary life sciences organizations, offering substantial cash value to Bio-Techne shareholders and positioning the combined entity to support various life science workflows.
Bio-Techne (TECH) has seen its stock price rebound significantly over the past three months, though it's been flat recently. The company is currently valued as 4% overvalued based on a framework that considers long-term trends in therapies and diagnostics, driven by chronic and age-related diseases. Investors are encouraged to assess the underlying metrics and risks, such as prolonged biotech funding pressure or tougher tariffs, to determine future investment opportunities.
Bio-Techne Corporation has released supplemental disclosures regarding its pending merger with Merck KGaA following a shareholder lawsuit and demand letters alleging misrepresentations in its proxy statement. The company denies the allegations but is providing additional information to avoid litigation and proceed with the shareholder vote. The disclosures clarify details about prior acquisition discussions, financial advisor engagement, and executive employment talks.